Fibrosis Lessens After Metabolic Surgery

Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma. Patients with MASH are also at risk for cardiovascular disease and mortality.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
• Non-Alcoholic Fatty Liver Disease
• Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Liver Fibrosis
• Obesity

Eligibility basics and study details

Study type

Interventional

Phase

Phase 4

Ages

18 to 75 years

Sex

All

Healthy volunteers

Accepted

Sponsor

The Cleveland Clinic

Last updated on ClinicalTrials.gov

July 31, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites